New quinolones in development
- 1 February 1994
- journal article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 3 (2) , 93-114
- https://doi.org/10.1517/13543784.3.2.93
Abstract
Fluoroquinolones, such as ciprofloxacin and ofloxacin have recently gained wide acceptance for use in the treatment of respiratory tract, skin/soft tissue, sexually transmitted diseases and urinary tract infections. The broad spectrum activity and good oral absorption characteristics of these antimicrobials promotes their use in both community and hospital settings. Despite these favourable properties, ciprofloxacin and ofloxacin have limited potency against some clinically important organsims, such as Streptococcus pneumoniae, enterococci and anaerobes including Bacteroides fragilis and many methicillin-resistant staphylococci. In addition, occasional clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa have emerged resistant to these compounds following their introduction. In an effort to expand upon the clinical utility of the existing fluoroquinolones, several new agents of this class have been identified and are in various stages of development. Some of these newer fluoroquinolones have significantly improved antimicrobial potency against the organisms mentioned above and/or possess pharmacokinetic characterisitics in humans that suggest they could be dosed less frequently than ciprofloxacin. This review will summarise the antimicrobial and human pharmacokinetic properties of sparfloxacin, clinafloxacin, PD-131628, PD-138312, PD-140248, Q-35, AM-1155, NM394, T-3761, rufloxacin, levofloxacin, CP-99,219, OPC-17116 and DU-6859a, which appear to be among the most interesting new fluoroquinolones currently in development. An attempt will be made to distinguish the most important characterisitics of these new agents, based upon the available preclinical data and results from single dose pharmacokinetic studies in humans. The data suggest that several of these fluoroquinolones possess properties that could translate into significant clinical advantages over the currently available compounds in this class.Keywords
This publication has 83 references indexed in Scilit:
- Mechanisms of clinical resistance to fluoroquinolones in Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 1991
- Inhibitory effects of ciprofloxacin and sparfloxacin on DNA gyrase purified from fluoroquinolone-resistant strains of methicillin-resistant Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 1991
- Book Review Statistics for Health Professionals By Susan Shott. 418 pp. Philadelphia, W.B. Saunders, 1990. $27.95.New England Journal of Medicine, 1991
- Ciprofloxacin resistance in coagulase-positive and -negative staphylococci: role of mutations at serine 84 in the DNA gyrase A protein of Staphylococcus aureus and Staphylococcus epidermidisAntimicrobial Agents and Chemotherapy, 1991
- Rapid Development of Ciprofloxacin Resistance in Methicillin-Susceptible and -Resistant Staphylococcus aureusThe Journal of Infectious Diseases, 1991
- Association with prior fluoroquinolone therapy of widespread ciprofloxacin resistance among gram-negative isolates in a Veterans Affairs medical centerAntimicrobial Agents and Chemotherapy, 1991
- DNA gyrase gyrA mutations in ciprofloxacin-resistant strains of Staphylococcus aureus: close similarity with quinolone resistance mutations in Escherichia coliJournal of Bacteriology, 1990
- First clinical isolate of highly fluoroquinolone-resistantEscherichia coli in scandanaviaEuropean Journal of Clinical Microbiology & Infectious Diseases, 1990
- Emergence of Ciprofloxacin Resistance in Nosocomial Methicillin-Resistant Staphylococcus aureus IsolatesArchives of internal medicine (1960), 1990
- In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinoloneAntimicrobial Agents and Chemotherapy, 1989